- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05875961
Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults
A Phase 1, Randomized, Observer-Blind, Multi-Center, Dose Ranging Study to Evaluate the Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted or Non-Adjuvanted Cell Culture-derived A/H2N3 Subunit Influenza Virus Vaccine in Healthy Subjects 18 Years and Above
This Phase 1, randomized, observer-blind, dose-ranging clinical study is evaluating 6 different formulations of MF59-adjuvanted and non-adjuvanted H2N3 influenza vaccine. Approximately 600 healthy adult subjects are to be randomized into 1 of 6 possible treatment groups with 100 subjects per group, stratified by age group (born after or before 1968). Each subject will receive an influenza vaccine injection on Day 1 and Day 22. Subjects will be followed up for approximately 12 months after the second vaccine injection.
The primary immunogenicity analysis is based on the Day 1, Day 8, Day 22, Day 29, and Day 43 serology data. The primary safety analysis is based on solicited local and systemic adverse events (AEs) reported within 10 days after each vaccination, unsolicited AEs reported within 3 weeks after each vaccination, and serious AEs (SAEs), medically attended AEs (MAAEs), AEs leading to withdrawal from the study, and AEs of special interest (AESIs) reported throughout the study.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Clinical Trial Disclosure Manager
- Phone Number: use email
- Email: seqirus.clinicaltrials@seqirus.com
Study Contact Backup
- Name: Medical Writing & Disclosures
Study Locations
-
-
-
Iloilo City, Philippines
- Recruiting
- West Visayas State University Medical Center
-
Manila, Philippines
- Recruiting
- Manila Doctors Hospital
-
Quezon City, Philippines
- Recruiting
- Quirino Memorial Medical Center
-
Silang, Philippines
- Recruiting
- Silang Specialists Medical Center
-
-
Cavite
-
Dasmariñas, Cavite, Philippines, 4114
- Withdrawn
- De La Salle Medical and Health Sciences Institute
-
-
-
-
Maryland
-
Rockville, Maryland, United States, 20854
- Active, not recruiting
- Meridian Clinical Research
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68510
- Active, not recruiting
- Meridian Clinical Research
-
Omaha, Nebraska, United States, 58134
- Active, not recruiting
- Meridian Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Individuals of 18 years of age and older on the day of informed consent who were not born in 1968.
- Individuals who have voluntarily given written informed consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry.
- Individuals who can comply with study procedures including follow-up.
- Males, females of non-childbearing potential or females of childbearing potential who are using an effective birth control method, at least 30 days prior to informed consent, which they intend to use for at least 2 months after the last study vaccination.
Exclusion Criteria:
- Females of childbearing potential who are pregnant, lactating, or who have not adhered to a specified set of contraceptive methods from at least 30 days prior to study entry and who do not plan to do so until 2 months after the last study vaccination.
- A body mass index (BMI) ≥35 kg/m2.
- Progressive, unstable, or uncontrolled clinical conditions as per investigator's assessment. Subjects must be stable and unchanged for a minimum of 3 months.
- Hypersensitivity, including allergy, to any component of vaccines, medicinal products or medical equipment whose use is foreseen in this study.
- Clinical conditions representing a contraindication to intramuscular vaccination and blood draws.
Abnormal function of the immune system resulting from:
- Clinical conditions.
- Systemic administration of corticosteroids at a dose of ≥20 mg/day of prednisone or equivalent for more than 14 consecutive days within 90 days prior to informed consent. Topical, inhaled and intranasal corticosteroids are permitted. Intermittent use (one dose in 30 days) of intra-articular corticosteroids are also permitted.
- Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to informed consent.
- History of any medical condition considered an adverse event of special interest (AESI).
- Received immunoglobulins with immunomodulating effects or any blood products within 180 days prior to informed consent.
- Received an investigational or non-registered medicinal product within 30 days prior to informed consent.
- Study personnel or immediate family or household member of study personnel.
- Any other clinical condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subject due to participation in the study.
- Individuals who received any other vaccines (with the exception of COVID-19 vaccines) within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrolment in this study or who are planning to receive any vaccine within 28 days from the study vaccines.
- Receipt of any (investigational or licensed) COVID-19 vaccine within 14 days (non-replicating vaccines) or 28 days (replicating vaccines) prior to enrollment or plan to receive any COVID-19 vaccine within 14 days from study vaccination.
- A known history of Guillain-Barre Syndrome or other demyelinating diseases such as encephalomyelitis and transverse myelitis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A
Eligible subjects who have been randomized to receive two intramuscular vaccinations (3 weeks apart) of low dose A/H2N3c + standard dose MF59 adjuvant
|
Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
|
Experimental: Group B
Eligible subjects who have been randomized to receive two intramuscular vaccinations (3 weeks apart) of intermediate dose A/H2N3c + standard dose MF59 adjuvant
|
Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
|
Experimental: Group C
Eligible subjects who have been randomized to receive two intramuscular vaccinations (3 weeks apart) of high dose A/H2N3c + standard dose MF59 adjuvant
|
Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
|
Experimental: Group D
Eligible subjects who have been randomized to receive two intramuscular vaccinations (3 weeks apart) of high dose A/H2N3c non-adjuvanted
|
Two intramuscular injections (3 weeks apart) of cell culture-derived non-adjuvanted H2N3 vaccine
|
Experimental: Group E
Eligible subjects who have been randomized to receive two intramuscular vaccinations (3 weeks apart) of lowest dose A/H2N3c + high dose MF59 adjuvant
|
Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
|
Experimental: Group F
Eligible subjects who have been randomized to receive two intramuscular vaccinations (3 weeks apart) of low dose A/H2N3c + high dose MF59 adjuvant
|
Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Geometric mean titer (GMT) of hemagglutination inhibition (HI) antibodies against homologous H2N3 strain - Day 1
Time Frame: Day 1
|
GMT (HI) prevaccination
|
Day 1
|
GMT of HI antibodies against homologous H2N3 strain - Day 8
Time Frame: Day 8
|
GMT (HI) 1 week postvaccination 1
|
Day 8
|
GMT of HI antibodies against homologous H2N3 strain Day 22
Time Frame: Day 22
|
GMT (HI) 3 weeks postvaccination 1
|
Day 22
|
GMT of HI antibodies against homologous H2N3 strain - Day 29
Time Frame: Day 29
|
GMT (HI) 1 week postvaccination 2
|
Day 29
|
GMT of HI antibodies against homologous H2N3 strain - Day 43
Time Frame: Day 43
|
GMT (HI) 3 weeks postvaccination 2
|
Day 43
|
GMT of microneutralization (MN) antibodies against homologous H2N3 strain - Day 1
Time Frame: Day 1
|
GMT (MN) prevaccination
|
Day 1
|
GMT of MN antibodies against homologous H2N3 strain - Day 8
Time Frame: Day 8
|
GMT (MN) 1 week postvaccination 1
|
Day 8
|
GMT of MN antibodies against homologous H2N3 strain - Day 22
Time Frame: Day 22
|
GMT (MN) 3 weeks postvaccination 1
|
Day 22
|
GMT of MN antibodies against homologous H2N3 strain - Day 29
Time Frame: Day 29
|
GMT (MN) 1 week postvaccination 2
|
Day 29
|
GMT of MN antibodies against homologous H2N3 strain - Day 43
Time Frame: Day 43
|
GMT (MN) 3 weeks postvaccination 2
|
Day 43
|
Geometric mean fold increase (GMFI) of HI antibodies against homologous H2N3 strain - Day 8
Time Frame: Day 8
|
GMFI (HI) 1 week postvaccination 1 compared to prevaccination
|
Day 8
|
GMFI of HI antibodies against homologous H2N3 strain - Day 22
Time Frame: Day 22
|
GMFI (HI) 3 weeks postvaccination 1 compared to prevaccination
|
Day 22
|
GMFI of HI antibodies against homologous H2N3 strain - Day 29
Time Frame: Day 29
|
GMFI (HI) 1 week postvaccination 2 compared to prevaccination
|
Day 29
|
GMFI of HI antibodies against homologous H2N3 strain - Day 43
Time Frame: Day 43
|
GMFI (HI) 3 weeks postvaccination 2 compared to prevaccination
|
Day 43
|
GMFI of MN antibodies against homologous H2N3 strain - Day 8
Time Frame: Day 8
|
GMFI (MN) 1 week postvaccination 1 compared to prevaccination
|
Day 8
|
GMFI of MN antibodies against homologous H2N3 strain - Day 22
Time Frame: Day 22
|
GMFI (MN) 3 weeks postvaccination 1 compared to prevaccination
|
Day 22
|
GMFI of MN antibodies against homologous H2N3 strain - Day 29
Time Frame: Day 29
|
GMFI (MN) 1 week postvaccination 2 compared to prevaccination
|
Day 29
|
GMFI of MN antibodies against homologous H2N3 strain - Day 43
Time Frame: Day 43
|
GMFI (MN) 3 weeks postvaccination 2 compared to prevaccination
|
Day 43
|
Percentages of subjects with HI titers ≥1:40 against homologous H2N3 strain - Day 1
Time Frame: Day 1
|
% ≥1:40 (HI) prevaccination
|
Day 1
|
Percentages of subjects with HI titers ≥1:40 against homologous H2N3 strain - Day 8
Time Frame: Day 8
|
% ≥1:40 (HI) 1 week postvaccination 1
|
Day 8
|
Percentages of subjects with HI titers ≥1:40 against homologous H2N3 strain - Day 22
Time Frame: Day 22
|
% ≥1:40 (HI) 3 weeks postvaccination 1
|
Day 22
|
Percentages of subjects with HI titers ≥1:40 against homologous H2N3 strain - Day 29
Time Frame: Day 29
|
% ≥1:40 (HI) 1 week postvaccination 2
|
Day 29
|
Percentages of subjects with HI titers ≥1:40 against homologous H2N3 strain - Day 43
Time Frame: Day 43
|
% ≥1:40 (HI) 3 weeks postvaccination 2
|
Day 43
|
Percentages of subjects with MN titers ≥1:40 against homologous H2N3 strain - Day 1
Time Frame: Day 1
|
% ≥1:40 (MN) prevaccination
|
Day 1
|
Percentages of subjects with MN titers ≥1:40 against homologous H2N3 strain - Day 8
Time Frame: Day 8
|
% ≥1:40 (MN) 1 week postvaccination 1
|
Day 8
|
Percentages of subjects with MN titers ≥1:40 against homologous H2N3 strain - Day 22
Time Frame: Day 22
|
% ≥1:40 (MN) 3 weeks postvaccination 1
|
Day 22
|
Percentages of subjects with MN titers ≥1:40 against homologous H2N3 strain - Day 29
Time Frame: Day 29
|
% ≥1:40 (MN) 1 week postvaccination 2
|
Day 29
|
Percentages of subjects with MN titers ≥1:40 against homologous H2N3 strain - Day 43
Time Frame: Day 43
|
% ≥1:40 (MN) 3 weeks postvaccination 2
|
Day 43
|
Percentages of subjects with seroconversion by HI against homologous H2N3 strain - Day 8
Time Frame: Day 8
|
% seroconversion (HI) 1 week postvaccination 1, defined as a ≥4-fold increase in HI titer postvaccination in those with prevaccination titer ≥1:10, or a postvaccination HI titer ≥1:40 for subjects with baseline titer <1:10
|
Day 8
|
Percentages of subjects with seroconversion by HI against homologous H2N3 strain - Day 22
Time Frame: Day 22
|
% seroconversion (HI) 3 weeks postvaccination 1, defined as a ≥4-fold increase in HI titer postvaccination in those with prevaccination titer ≥1:10, or a postvaccination HI titer ≥1:40 for subjects with baseline titer <1:10
|
Day 22
|
Percentages of subjects with seroconversion by HI against homologous H2N3 strain - Day 29
Time Frame: Day 29
|
% seroconversion (HI) 1 week postvaccination 2, defined as a ≥4-fold increase in HI titer postvaccination in those with prevaccination titer ≥1:10, or a postvaccination HI titer ≥1:40 for subjects with baseline titer <1:10
|
Day 29
|
Percentages of subjects with seroconversion by HI against homologous H2N3 strain - Day 43
Time Frame: Day 43
|
% seroconversion (HI) 3 weeks postvaccination 2, defined as a ≥4-fold increase in HI titer postvaccination in those with prevaccination titer ≥1:10, or a postvaccination HI titer ≥1:40 for subjects with baseline titer <1:10
|
Day 43
|
Percentages of subjects with seroconversion by MN against homologous H2N3 strain - Day 8
Time Frame: Day 8
|
% seroconversion (MN) 1 week postvaccination 1, defined as a ≥4-fold increase in MN titer postvaccination in those with prevaccination titer ≥lower limit of quantification (LLOQ), or a postvaccination MN titer ≥4×LLOQ for subjects with baseline titer <LLOQ
|
Day 8
|
Percentages of subjects with seroconversion by MN against homologous H2N3 strain - Day 22
Time Frame: Day 22
|
% seroconversion (MN) 3 weeks postvaccination 1, defined as a ≥4-fold increase in MN titer postvaccination in those with prevaccination titer ≥lower limit of quantification (LLOQ), or a postvaccination MN titer ≥4×LLOQ for subjects with baseline titer <LLOQ
|
Day 22
|
Percentages of subjects with seroconversion by MN against homologous H2N3 strain - Day 29
Time Frame: Day 29
|
% seroconversion (MN) 1 week postvaccination 2, defined as a ≥4-fold increase in MN titer postvaccination in those with prevaccination titer ≥lower limit of quantification (LLOQ), or a postvaccination MN titer ≥4×LLOQ for subjects with baseline titer <LLOQ
|
Day 29
|
Percentages of subjects with seroconversion by MN against homologous H2N3 strain - Day 43
Time Frame: Day 43
|
% seroconversion (MN) 3 weeks postvaccination 2, defined as a ≥4-fold increase in MN titer postvaccination in those with prevaccination titer ≥lower limit of quantification (LLOQ), or a postvaccination MN titer ≥4×LLOQ for subjects with baseline titer <LLOQ
|
Day 43
|
Number and percentages of subjects reporting solicited local and systemic adverse events (AEs) - Day 1 through Day 10
Time Frame: Day 1 through Day 10
|
10 consecutive days postvaccination 1
|
Day 1 through Day 10
|
Number and percentages of subjects reporting solicited local and systemic AEs - Day 22 through Day 31
Time Frame: Day 22 through Day 31
|
10 consecutive days postvaccination 2
|
Day 22 through Day 31
|
Number and percentage of subjects reporting any unsolicited AEs
Time Frame: Day 1 through Day 43
|
For 3 weeks following each vaccination
|
Day 1 through Day 43
|
Number and percentage of subjects reporting serious AEs (SAEs), AEs leading to withdrawal, AEs of special interest (AESI) and medically attended AEs (MAAEs)
Time Frame: Day 1 through Day 387
|
From vaccination until study completion
|
Day 1 through Day 387
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
GMT of ELLA titers as a measure of anti-neuraminidase (NA) immunogenicity
Time Frame: Day 1, Day 8, Day 22, Day 29, Day 43
|
GMT (ELLA) prevaccination, 1 and 3 weeks postvaccination
|
Day 1, Day 8, Day 22, Day 29, Day 43
|
GMFI of ELLA titers as a measure of anti-NA immunogenicity
Time Frame: Day 8, Day 22, Day 29, Day 43
|
GMFI (ELLA) 1 and 3 weeks postvaccination compared to prevaccination
|
Day 8, Day 22, Day 29, Day 43
|
Percentage of subjects with ≥4-fold increase in ELLA titer as a measure of anti-NA immunogenicity
Time Frame: Day 8, Day 22, Day 29, Day 43
|
% ≥4-fold increase (ELLA) 1 and 3 weeks postvaccination compared to prevaccination
|
Day 8, Day 22, Day 29, Day 43
|
GMT of HI antibodies against homologous H2N3 strain - Persistence
Time Frame: Day 202, Day 387
|
GMT (HI) 6 and 12 months postvaccination 2
|
Day 202, Day 387
|
GMT of MN antibodies against homologous H2N3 strain - Persistence
Time Frame: Day 202, Day 387
|
GMT (MN) 6 and 12 months postvaccination 2
|
Day 202, Day 387
|
GMT of ELLA titer as a measure of anti-NA immunogenicity- Persistence
Time Frame: Day 202, Day 387
|
GMT (ELLA) 6 and 12 months postvaccination 2
|
Day 202, Day 387
|
GMFI of HI antibodies against homologous H2N3 strain - Persistence
Time Frame: Day 202, Day 387
|
GMFI (HI) 6 and 12 months postvaccination 2 compared to prevaccination
|
Day 202, Day 387
|
GMFI of MN antibodies against homologous H2N3 strain - Persistence
Time Frame: Day 202, Day 387
|
GMFI (MN) 6 and 12 months postvaccination 2 compared to prevaccination
|
Day 202, Day 387
|
GMFI of ELLA titer as a measure of anti-NA immunogenicity- Persistence
Time Frame: Day 202, Day 387
|
GMFI (ELLA) 6 and 12 months postvaccination 2 compared to prevaccination
|
Day 202, Day 387
|
Percentages of subjects with HI titers ≥1:40 against homologous H2N3 strain - Persistence
Time Frame: Day 202, Day 387
|
% ≥1:40 (HI) 6 and 12 months postvaccination 2
|
Day 202, Day 387
|
Percentages of subjects with MN titers ≥1:40, ≥1:80 and ≥1:160 against homologous H2N3 strain - Persistence
Time Frame: Day 202, Day 387
|
% ≥1:40, ≥1:80 and ≥1:160 (MN) 6 and 12 months postvaccination 2
|
Day 202, Day 387
|
Percentages of subjects with seroconversion by HI against homologous H2N3 strain - Persistence
Time Frame: Day 202, Day 387
|
% seroconversion (HI) 6 and 12 months postvaccination 2, defined as a ≥4-fold increase in HI titer postvaccination in those with prevaccination titer ≥1:10, or a postvaccination HI titer ≥1:40 for subjects with baseline titer <1:10
|
Day 202, Day 387
|
Percentages of subjects with seroconversion by MN against homologous H2N3 strain - Persistence
Time Frame: Day 202, Day 387
|
% seroconversion (MN) 6 and 12 months postvaccination 2, defined as a ≥4-fold increase in MN titer postvaccination in those with prevaccination titer ≥LLOQ, or a postvaccination MN titer ≥4×LLOQ for subjects with baseline titer <LLOQ
|
Day 202, Day 387
|
Percentage of subjects with ≥4-fold increase in ELLA titer as a measure of anti-NA immunogenicity - Persistence
Time Frame: Day 202, Day 387
|
% ≥4-fold increase (ELLA) 6 and 12 months postvaccination 2 compared to prevaccination
|
Day 202, Day 387
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Clinical Science & Strategy, Seqirus
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- RNA Virus Infections
- Respiratory Tract Diseases
- Disease Attributes
- Orthomyxoviridae Infections
- Infections
- Communicable Diseases
- Virus Diseases
- Influenza, Human
- Respiratory Tract Infections
- Physiological Effects of Drugs
- Immunologic Factors
- Adjuvants, Immunologic
- MF59 oil emulsion
Other Study ID Numbers
- V204_01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infections
-
International Centre for Diarrhoeal Disease Research...Centers for Disease Control and PreventionNot yet recruitingMeasles | Rubella | Cholera | Typhoid
-
MJM BontenJanssen Research & Development, LLC; Innovative Medicines InitiativeCompletedE.Coli InfectionsUnited States, United Kingdom, Canada, France, Germany, Italy, Japan, Spain
-
PfizerCompletedGroup B Streptococcus InfectionsUnited States, South Africa, United Kingdom
-
GlaxoSmithKlineActive, not recruitingInfections, MeningococcalFinland, Poland, Spain, United Kingdom, Germany, South Africa, Dominican Republic, Israel, Honduras
-
PfizerCompletedInfections, MeningococcalAustralia, Canada, Czechia, Panama, South Africa, Turkey
-
GlaxoSmithKlineCompletedInfections, MeningococcalFinland
-
PfizerCompletedInfections, MeningococcalPhilippines
-
GlaxoSmithKlineCompletedInfections, MeningococcalUnited States, Finland, Poland
-
GlaxoSmithKlineCompleted
Clinical Trials on Low dose A/H2N3c + standard dose MF59
-
Kyoung Ho Lee, MDSeoul National University Bundang Hospital; Ministry of Health & Welfare, Korea and other collaboratorsCompleted
-
Institute of Liver and Biliary Sciences, IndiaCompletedSpontaneous Bacterial PeritonitisIndia
-
National Institute of Diabetes and Digestive and...Washington University School of Medicine; University of Alabama at Birmingham; Icahn School of Medicine at Mount Sinai and other collaboratorsCompletedEnd Stage Renal DiseaseUnited States
-
Karolinska InstitutetCompletedEvaluate CBCT Protocols in Subjective Image QualitySweden
-
Xuzhou Central HospitalCompletedLung Cancer | Lung; NodeChina
-
Seoul National University Bundang HospitalGE Healthcare; National Research Foundation of KoreaCompletedAppendicitisKorea, Republic of
-
Sanofi Pasteur, a Sanofi CompanyCompletedInfluenza | Healthy VolunteersUnited States
-
Zhejiang UniversityCompletedHyperlipoproteinemia
-
Seoul National University HospitalActive, not recruiting
-
Xuzhou Central HospitalCompletedLung Cancer, Adenocarcinoma | Lung Inflammatory PseudotumorChina